Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
291,104
52-wk High
$3.66
52-wk Low
$0.37

CYTR.OQ

Chart for CYTR.OQ

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $49.28
Shares Outstanding(Mil.): 117.32
Dividend: --
Yield (%): --

Financials

  CYTR.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.68 -- --
ROI: -116.26 -2.56 13.01
ROE: -155.40 5.14 14.16

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

Nov 29 2016

BRIEF-Cytrx presents positive interim results from on-going clinical trial

* Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen

Nov 11 2016

BRIEF-Cytrx Q3 loss $0.13/shr

* Cytrx Corp - during Q3, embarked on a plan to reduce spending until additional results from Aldoxorubicin phase 3 STS clinical trial are available

Nov 09 2016

More From Around the Web

Earnings vs. Estimates